In 2023, antidepressant medicine sales in Canada reached an estimated $1.25 billion USD. From 2024 onwards, we observe steady growth: $1.28 billion in 2024, and reaching $1.33 billion by 2028. The year-on-year growth rates exhibit a slight, yet consistent increase, with an average compound annual growth rate (CAGR) of approximately 1% over the five-year forecast period.
Future trends to watch for include the impact of increasing public awareness and destigmatization of mental health issues, potential policy changes enhancing healthcare coverage, and introduction of innovative therapeutic solutions. These factors could substantially influence market dynamics and growth trajectory.
